Jerome B. Zeldis
Jerome B. Zeldis's purchase track record
How the stock did after each of Jerome B. Zeldis's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/20/2024 | NXGL | $10K | +6.1% | -32.7% | -1.2% |
| 8/23/2024 | NXGL | $25K | +27.7% | +27.7% | +6.7% |
| 5/26/2023 | NXGL | $12K | -7.4% | -19.7% | +8.4% |
| 3/25/2022 | NXGL | $10K | -15.3% | -13.8% | -18.7% |
| 12/27/2021 | NXGL | $50K | -40.0% | -42.5% | -18.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
NXGL Listed Among 12 Health Care Stocks Moving in Pre‑Market Session. NXGL was one of 12 health‑care stocks that moved in Wednesday’s pre‑market session. The move reflects short‑term interest in the sector. The stock is trading near its 52‑week low and has a low RSI, which may have contributed to the pre‑market activity.
Transaction History
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/2/2026 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/3/2025 | View on chart |
| PTCT | ▼ Sell | Open Market | 8,813 | $453K | 12/2/2024 | View on chart |
| PTCT | ▼ Sell | Open Market | 3,187 | $167K | 12/2/2024 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 12,000 | $370K | 12/2/2024 | View on chart |
| PTCT | ▼ Sell | Open Market | 5,699 | $288K | 12/2/2024 | View on chart |
| PTCT | ▼ Sell | Open Market | 2,634 | $135K | 12/2/2024 | View on chart |
| PTCT | ▼ Sell | Open Market | 3,667 | $192K | 12/2/2024 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 12,000 | $612K | 12/2/2024 | View on chart |
| NXGL | ▲ Buy | Open Market | 3,636 | $10K | 11/20/2024 | View on chart |
| NXGL | ▲ Buy | Open Market | 10,000 | $25K | 8/23/2024 | View on chart |
| PTCT | ▲ Buy | Option Exercise | 20,000 | $528K | 5/22/2024 | View on chart |
| PTCT | ▼ Sell | Open Market | 20,000 | $765K | 5/22/2024 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 2/15/2024 | View on chart |
| NXGL | ▲ Buy | Open Market | 5,000 | $12K | 5/26/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 4,000 | $0 | 1/5/2023 | View on chart |
| NXGL | ▲ Buy | Open Market | 5,300 | $10K | 3/25/2022 | View on chart |
| PTCT | ▲ Buy | Grant | 3,200 | $0 | 1/7/2022 | View on chart |
| NXGL | ▲ Buy | Open Market | 9,091 | $50K | 12/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29
PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.